Sugi Predict

Sugi Predict / Compounds / SCHEMBL20567607

SCHEMBL20567607

SCHEMBL20567607

Oc1cccc(-c2cncnc2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B1 P14061 12/20 0.60
▸ HSD17B2 P37059 11/20 0.60
▸ CYP3A4 P08684 6/20 0.60
▸ CYP2C9 P11712 4/20 0.60
▸ ATM Q13315 1/20 0.54
▸ PIK3CG P48736 1/20 0.51
▸ ESR1 P03372 2/20 0.50
▸ ESR2 Q92731 2/20 0.50
▸ CYP1A2 P05177 2/20 0.50
▸ CYP2D6 P10635 2/20 0.50
▸ CYP2B6 P20813 2/20 0.50
▸ CYP2C19 P33261 2/20 0.50
▸ CYP2A6 P11509 1/20 0.50
▸ CYP19A1 P11511 2/20 0.49
▸ CYP11B1 P15538 2/20 0.49
▸ CYP11B2 P19099 2/20 0.49
▸ CYP17A1 P05093 1/20 0.49
▸ METAP2 P50579 1/20 0.47
▸ CA12 O43570 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30302092 1.00 HSD17B1 (0.60) HSD17B1HSD17B2CYP3A4CYP2C9ATM
SCHEMBL22089054 0.84 ATM (0.67) CYP3A4ATMESR1CYP1A2CYP2A6
SCHEMBL22428530 0.81 ATM (0.64) CYP3A4CYP2C9ATMESR1CYP1A2
SCHEMBL22428553 0.81 ATM (0.64) CYP3A4CYP2C9ATMESR1CYP1A2
SCHEMBL29567050 0.81 CYP11B1 (0.68) HSD17B1HSD17B2CYP3A4CYP2C9CYP1A2
SCHEMBL1026845 0.81 CYP11B1 (0.68) HSD17B1HSD17B2CYP3A4CYP2C9CYP1A2
SCHEMBL30295066 0.81 CYP11B1 (0.68) HSD17B1HSD17B2CYP3A4CYP2C9CYP1A2
SCHEMBL69369 0.81 HSD17B1 (0.88) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL29551999 0.81 HSD17B1 (0.88) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
Bromide SCHEMBL7553957 0.79 CYP11B1 (0.66) HSD17B1HSD17B2CYP3A4CYP2C9CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258340-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2025-03-25 — — US disclosed
CN-116473965-A Pyrazole MAGL inhibitors H.隆德贝克有限公司 2023-07-25 — — CN disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 — — US disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 — — US disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 — — US disclosed
EP-4198024-A1 PYRAZOLE MAGL INHIBITORS H. Lundbeck A/S (DK) 2023-06-21 — — EP disclosed
EP-4198024-A1 PYRAZOLE MAGL INHIBITORS H. Lundbeck A/S (DK) 2023-06-21 — — EP disclosed
US-11655217-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2023-05-23 — — US disclosed
US-11655217-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2023-05-23 — — US disclosed
US-11655217-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2023-05-23 — — US disclosed
US-10927105-B1 Pyrazole MAGL inhibitors LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2021-02-23 — — US disclosed
EP-3630744-A1 PYRAZOLE MAGL INHIBITORS Lundbeck La Jolla Research Center, Inc. (US) 2020-04-08 — — EP disclosed
CN-110678456-A Pyrazole MAGL inhibitors 隆德贝克拉荷亚研究中心有限公司 2020-01-10 — — CN disclosed
US-10266497-B2 Pyrazole MAGL inhibitors ABIDE THERAPEUTICS, INC. (US) 2019-04-23 — — US disclosed
US-10266497-B2 Pyrazole MAGL inhibitors ABIDE THERAPEUTICS, INC. (US) 2019-04-23 — — US disclosed
US-20180339970-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2018-11-29 — — US disclosed
WO-2018217805-A1 PYRAZOLE MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-11-29 — — WO disclosed
CN-102014900-B Method of treating cancer using a neuropeptide Y5R (NPY5R) antagonist UNIV HEALTH NETWORK 2014-04-02 — — CN disclosed
CN-102014900-A Method of treating cancer using a neuropeptide Y5R (NPY5R) antagonist UNIV HEALTH NETWORK 2011-04-13 — — CN disclosed
CN-101027075-A Combination therapy for the treatment of obesity MERCK & CO INC (US) 2007-08-29 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180339970-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL HSD17B1 1293/4885HSD17B2 1852/4885CYP3A4 532/4885
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL HSD17B1 1293/4885HSD17B2 1852/4885CYP3A4 532/4885
US-12258340-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL HSD17B1 1300/4885HSD17B2 1933/4885CYP3A4 572/4885
US-10266497-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL HSD17B1 1293/4885HSD17B2 1852/4885CYP3A4 532/4885
US-11655217-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL HSD17B1 1300/4885HSD17B2 1933/4885CYP3A4 572/4885
US-10927105-B1 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL HSD17B1 1293/4885HSD17B2 1852/4885CYP3A4 532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.